[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571464":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":69,"collaborators":23,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":23,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":23,"enrollmentInfo":81,"targetDuration":23,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":50,"whyStopped":23,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"PDE5 Inhibitor Therapy in Men with Vasculogenic Erectile Dysfunction (ED)","ACTIVE_COMPARATOR","Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: Daily low-dose PDE5 inhibitor therapy. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.",[13],"Drug: Daily low-dose PDE5 inhibitor therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Testosterone Therapy in Hypogonadal Men","Population: 40 hypogonadal men aged 18 or above Intervention: Testosterone therapy as per clinical guidelines. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.",[18],"Drug: Testosterone therapy as per clinical guidelines.",{"label":20,"type":21,"description":22,"interventionNames":23},"Vasculogenic ED confirmed by penile Doppler ultrasound","NO_INTERVENTION","Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: None Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.",null,[25,30],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":23},"DRUG","Daily low-dose PDE5 inhibitor therapy","Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.",[9],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":23},"Testosterone therapy as per clinical guidelines.","Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.",[15],[35],{"name":36,"affiliation":5,"role":37},"Faysal A Yafi, MD","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":23,"email":43},"Muhammed AM Hammad, MBBCh","CONTACT","714-456-7005","mahammad@hs.uci.edu",{"name":45,"role":41,"phone":42,"phoneExt":23,"email":46},"Elia Abou Chawareb, MD","eaboucha@hotmail.com",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"UCI Urology | Men's Health Center","RECRUITING","Newport Beach","California","92660","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-117.92895,33.61891,{"lat":60,"lon":59},[63,66,68],{"name":64,"role":41,"phone":65,"phoneExt":23,"email":43},"Muhammed AM Hammad, Mbbch","7144567005",{"name":45,"role":41,"phone":65,"phoneExt":23,"email":67},"eaboucha@hs.uci.edu",{"name":36,"role":37,"phone":23,"phoneExt":23,"email":23},{"type":37,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Faysal Yafi","Associate Professor of Urology Director of Men's Health and Newport Urology Chief, Division of Men's Health and Reconstructive Urology","100571464","endopat-device-for-endothelial-dysfunction-in-ed-100571464",false,"NCT06720597","EndoPAT Device for Endothelial Dysfunction in ED","Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy","Inclusion Criteria:\n\n* Males 18 years old and above\n* Diagnosed with erectile dysfunction or hypogonadism\n\nExclusion Criteria:\n\n* Patients without the above criteria","MALE","18 Years",{"count":82,"type":83},120,"ESTIMATED","INTERVENTIONAL",[86],"NA","To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound.\n\nTo evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy.\n\nTo investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy",[89,90,91],"Erectile Dysfunction","Hypogonadism, Male","Endothelial Dysfunction",[93,89,94,91,95,96],"EndoPAT","Hypogonadism","ED","Testosterone","2026-01-29",{"date":99,"type":100},"2026-02-02","ACTUAL",{"date":102,"type":100},"2025-08-13",{"date":104,"type":83},"2027-01",{"name":5,"class":6},1]